| Code | CSB-RA004937MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to TNX-1500, targeting CD40 ligand (CD40LG, also known as CD154). CD40LG is a type II transmembrane protein primarily expressed on activated T cells that plays a critical role in immune regulation by binding to CD40 on antigen-presenting cells. This interaction is essential for T cell-dependent B cell activation, immunoglobulin class switching, and the formation of germinal centers. Dysregulated CD40-CD40LG signaling contributes to various autoimmune and inflammatory conditions, including systemic lupus erythematosus, rheumatoid arthritis, and transplant rejection, making this pathway an important therapeutic target.
TNX-1500 is a clinical-stage therapeutic antibody designed to block CD40LG-CD40 interactions without inducing thromboembolic complications associated with earlier anti-CD40LG antibodies. This biosimilar provides researchers with a valuable tool for investigating CD40LG-mediated immune responses, studying autoimmune disease mechanisms, evaluating therapeutic blocking strategies, and exploring novel immunomodulatory approaches in preclinical models.
There are currently no reviews for this product.